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Clinical significance of tumor volume and lymph node 
involvement assessed by MRI in stage IIB cervical cancer 
patients treated with concurrent chemoradiation therapy
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Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, 
1Yonsei University College of Medicine, 2Kwandong University College of Medicine, Seoul, Korea
Objective: The purpose of this study was to evaluate the prognostic significance of tumor volume assessed by 
pretreatment MRI in stage IIB cervical cancer patients with concurrent chemoradiation therapy. 
Methods: A retrospective chart review was performed on seventy five patients with cervical cancer who were treated 
with concurrent weekly cisplatin (40 mg/m2) and radiotherapy between January 2000 and April 2007. Potential 
prognostic factors were age, chemotherapy numbers, histology, tumor diameter and volume, lymph node (LN) 
involvement and pretreatment squamous cell carcinoma antigen (SCC-Ag) levels.
Results: The median follow-up time was 55 months (range, 8 to 104 months). The median tumor size and volume 
(range) were 4.5 cm (2 to 10) and 33.1 mL (4.2 to 392.7), respectively. Pelvic LN enlargement rate was 58.7%. 
Para-aortic LN enlargement rate was 14.7%. Using multivariate analysis, a tumor volume (＞33 mL, p=0.025), pelvic 
LN enlargement (p=0.044) revealed a significantly unfavorable outcome on overall survival. PFS was influenced by 
tumor histology (p＜0.001), pelvic LN enlargement (p=0.015) and pretreatment SCC-Ag levels (p=0.018). We found 
that 22 (29.3%) patients had recurrences and 14 (18.7%) patients died of disease. The 5-year overall survival rate was 
80.6% (standard error, 4.9%) and 5-year PFS rate was 71.3% (standard error, 5.3%).
Conclusion: Tumor volume and pelvic LN involvement showed possibility to predict overall survival in patient with 
stage ⅡB cervical cancer. Optimal tumor volume and pelvic LN assessment by pretreatment MRI might be helpful to 
predict treatment outcome. 
Key Words: Cervical neoplasms, Chemoradiation therapy, MRI, Tumor volume
Received October 11, 2009, Revised January 8, 2010,
Accepted January 24, 2010
Correspondence to Young Tae Kim
Department of Obstetrics and Gynecology, Yonsei University College
of Medicine, 250 Seongsanno, Seodaemun-gu, Seoul 120-752, Korea
Tel: 82-2-2228-2230, Fax: 82-2-313-8357
E-mail: ytkchoi@yuhs.ac
INTRODUCTION
Cervical cancer is the only gynecological cancer staged clin-
ically according to the International Federation of Gynecology 
and Obstetrics (FIGO) classification system. However, clin-
ical staging has limitations in evaluation of several parameters 
including parametrial invasion, lymph node (LN) metastasis, 
pelvic wall invasion.1 Clinical evaluation of tumor size in cer-
vical cancer remains inaccurate when compared with surgical 
staging. Additionally the FIGO clinical staging system has 
limited accuracy with staging errors increasing for more ad-
vanced disease. Since National Cancer Institute (NCI) issued 
clinical announcement that noted the improved survival with 
concurrent chemoradiation therapy (CCRT) compared to ra-
diation alone among women with locally advanced cervical 
cancer in 1999, cisplatin-based combined chemotherarpy dur-
ing external beam irradiation has been a standard treatment.2 
It is known that increasing tumor size and volume affect over-
all survival and tumor recurrence.3,4 Pretreatment squamous 
cell carcinoma antigen (SCC-Ag) levels correlated with extent 
of disease, the response to treatment, and can be used to pre-
dict the tumor recurrence.5,6 In operable patients, accurate 
evaluations of tumor size, extension to surrounding tissue or 
LN metastasis are possible by pathologic report. However, 
prognostic factors assessment in inoperable patients who are 
planned for CCRT, should be evaluated by clinical examina-
tion and imaging studies.
Among imaging study modalities, magnetic resonance imag-
ing (MRI) has been widely used to evaluate the size and volume 
of primary tumor, parametrial invasion and LN enlargement. 
Although computed tomography (CT) and MRI have a com-
parable accuracy in staging, MRI is regarded as the most reliable 
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tool for the treatment planning of cervical cancer due to superior 
soft tissue contrast and multiplanar capability.7,8 Even though 
clinical stage is important prognostic factors, stage does not 
necessarily correlate with tumor size, volume, and LN 
involvement.9 And treatment outcome may vary according to 
tumor size, volume or other prognostic factors in patients with 
same stage IIB cervical cancer.
 The aim of this study was to evaluate the prognostic sig-
nificance of tumor size, volume and LN enlargement assessed 
by pretreatment MRI in presence of other prognostic factor 
such as age, histology, pretreatment SCC-Ag levels. 
MATERIALS AND METHODS
1. Patient population
A retrospective chart review of patient with stage IIB cervical 
cancer who received an MRI scan before curative aimed CCRT 
was performed. Between January 2000 and April 2007, sev-
enty five patients were treated with CCRT at the Yonsei 
University College of Medicine were diagnosed between. The 
cut-off date for follow-up was June 2008. 
The staging was based on FIGO classification system. The pro-
cedure for clinical staging included a medical history, physical 
examination, routine laboratory tests, chest radiography, intra-
venous pyelography, cystoscopy, sigmoidoscopy and MRI scan. 
LN diameter greater than 1 cm in minimum diameter were con-
sidered positive node. SCC-Ag levels were measured before the 
start of CCRT and 1 month after completing treatment. 
Potential prognostic factors were age, numbers of chemo-
therapy cycle, tumor histology, tumor diameter and volume, 
LN involvement and pretreatment SCC-Ag levels.
2. Treatment policy
Radiotherapy was delivered with a combination of external 
irradiation and high-dose rate intracavitary radiation by a re-
mote afterloading system using iridium192 sources (Gamma- 
Med II). External whole-pelvis irradiation was performed 
with a dose of 1.8 Gy per fraction 5 times per week to a midline 
dose of 27.0 to 36.0 Gy. This was followed by high-dose rate 
intracavitary radiation with 6 insertions (twice per week) 
with a fractional dose of 5.0 Gy to a total dose of 30.0 Gy at 
point A. After high-dose rate intracavitary radiation, patients 
received a second course of external irradiation with central 
shielding up to a total external dose of 45.0 to 50.4 Gy. In case 
of para-aortic LN enlargement on MRI, extended-field radia-
tion was administered. During radiotherapy, cisplatin was 
given intravenously once a week at a dose of 40 mg/m2 of body 
surface area (BSA) with the total dose not exceeding 70 mg per 
week. 
3. MRI imaging and tumor volume measurement
MRI was performed using a 1.5 Tesla scanner (INTERA 
ACHIEVA 1.5T; Philips Medical Systems, Best, Nederland) 
with a SENSE-body coil. Routine spin echo transverse, coronal, 
and sagittal plane T2 weighted images (TR/TE; 3632-4182/90 
ms, number of excitation (NEX); 2, section thickness; 5 mm, 
intersection gap; 2 mm, field of view; 24 cm, matrix; 512×256) 
and transverse spin-echo T1 weighted images (TR/TE; 678.2/11 
ms, NEX; 3, section thickness; 5 mm, intersection gap; 2 mm, 
field of view (FOV); 24 cm, matrix; 256×256) of the pelvis were 
acquired. Gradient echo precontrast fat suppressed sagittal T1 
weighted images (THRIVE : TR/TE 3.1×1.9 ms; NEX; 1, echo- 
train length; 48, flip angle; 10o, section thickness; 4 mm, inter-
section gap; 2 mm, field of view; 37 cm, matrix; 336×307) were 
obtained. A gadolinium chelate (Dotarem; Guerbet, Aulnay- 
sous-Bois, France) was administered intravenously at a dose 
of 0.2 mL per kilogram of body weight by hand injection. When 
contrast agent was seen at the pelvic aorta on the bolus tracking 
scan, 6 sequential sets of images were scanned during non-breath 
hold with a time interval of 20 seconds with parameters identi-
cal to the precontrast images. Contrast enhanced T1-weighted 
axial images (THRIVE: TR/TE=4.5/2.2 ms; NEX; 1, echo-train 
length; 60, flip angle; 15o, section thickness; 4 mm, intersection 
gap; 2 mm, field of view; 40 cm, matrix; 320×224) were 
obtained. The diameter-based calculation was computed by 
measuring the largest tumor diameter in each orthogonal plane 
on MRI scan. The longitudinal diameter (d1) along the long axis 
of the endometrial cavity on the sagittal images and the ante-
roposterior diameter (d2, orthogonal to the longitudinal diam-
eter) were measured on the sagittal images. The largest lateral 
diameter (d3) was measured on the axial images. Diameter-based 
measurements were computed as an ellipsoid (V=d1×d2×d3 
×π/6) to calculate diameter-based volume (V).
4. Statistical analysis
Overall survival (OS) was assessed from the date of CCRT to 
death from any cause or the date of last contact. Progression 
free survival (PFS) was measured from the treatment start to 
either progression/relapse or to the date of last contact for pa-
tients who are alive and progression free. Survival curves were 
measured by the Kaplan-Meier method. Differences in survival 
were compared using the log-rank statistical test. Prognostic 
factor analyses for OS and PFS were performed using Cox re-
gression method. Hazard ratio is given with 95% confidence in-
tervals (95% CI). SPSS 12.0 (SPSS Inc., Chicago, IL, USA) was 
used for the statistical analysis. A p-value ＜0.05 was consid-
ered to be statistically significant.
RESULTS
1. Patient characteristics
Seventy five patients were reviewed for this study. The pa-
tients and tumor-associated characteristics are summarized 
in Table 1. Fifty four patients (72.0%) received 6 cycles che-
motherapy, but nine patients (12.0%) did not complete plan-
ned chemotherapy. Forty four patients (58.7%) showed pelvic 
LN enlargement on MRI scan. Eleven patients (14.7%) ex-
hibited both pelvic and para-aortic LN enlargement. The me-
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Table 1. Patient characteristics (N=75)
Variables No. of patients (%)
Age, yr
 
Follow-up, mo 
Histology
 
No. of chemotherapy cycle
 
Lymph node involvement
 
Tumor diameter, cm 
Tumor volume, mL 
Pre-treatment SCC-Ag, ng/mL 
 (excluded adenocarcinoma)
Post-treatment SCC-Ag, ng/mL
 (excluded adenocarcinoma)
Median (range)
  ≤39
  40-49
  50-59
  60-69
  ≥70
Median (range)
Squamous cell
 carcinoma
Adenocarcinoma
Median (range)
  3-5
  6
  7-10
Pelvic
Para-aortic
Median (range)
Median (range)
Mean±SD  
Median (range)
Mean±SD
Median (range)
  51 (33-71)
7 (9.3)
30 (40.0)
19 (24.0)
18 (25.3)
1 (1.3)
  55 (8-104)
67 (89.3)
  8 (19.7)
  6 (3-10)
  9 (12.0)
54 (72.0)
12 (16.0)
44 (58.7)
11 (14.7)
4.5 (2-10)
33.1 (4.2-392.7)
7.9 ± 10.4
4.6 (0.1-61.2)
1.1±2.2
0.5 (13.7)
SCC-Ag: squamous cell carcinoma antigen.
Table 3. Univariate and multivariate analysis of prognostic factor for PFS (Cox proportional hazard) 
Variables
Univariate analysis Multivariate analysis
p-value Hazard ratio (95% CI) p-value Hazard ratio (95% CI)
Tumor histology (SCC, adenocarcinoma) 
Tumor diameter (＜4.5 cm, ≥4.5 cm)
Tumor volume (＜33 mL, ≥33 mL)
Pretreatment SCC-Ag* (＜4.5 ng/mL, ≥4.5 ng/mL)
Pelvic lymph node (negative, positive)
Para-aortic lymph node (negative, positive)
Age (＜50, ≥50 yr)
0.019
0.087
0.050
0.013
0.010
0.375
0.479
3.33 (1.22-9.12)
2.09 (0.89-4.83)
2.35 (1.00-5.51)
3.34 (1.28-8.66)
  4.15 (1.40-12.32)
1.64 (0.55-4.85)
0.74 (0.32-1.71)
0.000
0.507
0.018
0.015
18.38 (3.61-93.43)
1.38 (0.53-3.57)
  3.77 (1.25-11.31)
  6.78 (1.45-31.06)
PFS: progression free survival, SCC-Ag: squamous cell carcinoma antigen.
*Excluded adenocarcinoma.
Table 4. Five-yr overall survival (OS) for patient subgroup 
Variables No. of patients 5-yr OS (%) %SE
Age, yr
  ＜50
  ≥50
Histology
  Squamous cell carcinoma
  Adenocarcinoma
Tumor diameter, cm
  ＜4.5
  ≥4.5 
Tumor volume, mL
  ＜33
  ≥33 
No. of chemotherapy cycle
  ＜6
  ≥6
Pelvic lymph node 
  Negative
  Positive
Para-aortic lymph node 
  Negative
  Positive
Pretreatment SCC-Ag, ng/mL*
  ＜4.5
  ≥4.5
37
38
67
  8
45
30
47
28
  9
66
31
44
64
11
31
36
76.3
85.1
81.6
75.0
88.1
64.6
94.0
49.3
66.8
79.5
94.7
69.5
82.5
71.6
89.3
70.7
  7.5
  6.2
  5.1
15.3
  5.1
10.2
  3.9
12.3
20.8
  5.4
  5.1
  7.5
  5.1
14.0
  5.2
  8.5
SCC-Ag: squamous cell carcinoma antigen.
*Excluded adenocarcinoma.
Table 2. Site of recurrence
Site No. of patients (%)
Pelvic cavity
Pelvic sidewall
Distant metastasis
Pelvic cavity＋Pelvic sidewall 
Pelvic cavity＋Distant metastasis
Pelvic sidewall＋Distant metastasis
4 (5.3)
2 (2.7)
  8 (10.7)
1 (1.3)
6 (8.0)
1 (1.3)
dian tumor diameter and volume were 4.5 cm (range, 2 to 10 
cm) and 33.1 mL (range, 4.2 to 392.7 mL), respectively. 
2. Progression free survival 
Twenty two patients (29.3%) had recurred. Eight patients 
had developed distant metastasis and 7 patients developed 
both local and distant metastasis (Table 2). The 5-year PFS 
rate was 71.3% (standard error, 5.3%). In univariate analysis, 
tumor histology, tumor volume, pretreatment SCC-Ag levels 
and pelvic LN involvement were statistically significant prog-
nostic factor on PFS. By multivariate analysis of PFS according 
to these factors, tumor histology (squamous cell carcinoma), 
SCC-Ag levels (≥4.5 ng/mL) and pelvic LN involvement 
showed statistically significant factors on PFS (Table 3).
3. Overall survival
Among seventy five patients, 14 (18.7%) have died. The 
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Fig. 1. Overall survival curves for (A) pelvic LN involvement (left, p=0.044) and (B) tumor volume (right, p=0.025). PN: pelvic lymph node.
Table 5. Univariate and multivariate analysis of prognostic factor for overall survival (Cox proportional hazard) 
Variables
Univariate analysis Multivariate analysis
p-value Hazard ratio (95% CI) p-value Hazard ratio (95% CI)
Tumor histology (SCC, adenocarcinoma)
Tumor diameter (＜4.5 cm, ≥4.5 cm)
Tumor volume (＜33 mL, ≥33 mL)
Pretreatment SCC-Ag* (＜4.5 ng/mL, ≥4.5 ng/mL)
Pelvic lymph node (negative, positive)
Para-aortic lymph node (negative, positive)
Age (＜50, ≥50 yr)
0.330
0.026
0.001
0.044
0.019
0.199
0.503
2.22 (0.47-9.71)
3.33 (1.15-9.61)
  6.25 (2.09-18.75)
  3.30 (1.03-10.59)
11.47 (1.50-87.81)
2.33 (0.64-8.42)
0.70 (0.24-2.01)
0.314
0.025
0.426
0.044
  0.38 (0.060-2.49)
  8.31 (1.30-53.15)
1.64 (0.48-5.58)
  9.80 (1.07-90.09)
SCC-Ag: squamous cell carcinoma antigen.
*Excluded adenocarcinoma.
5-year OS rate was 80.6% (standard error, 4.9%). Estimated 
(Kaplan-Meier) five-year survival rate according to patient 
subgroups were summarized in Table 4. The 5-year survival 
rate of patients with tumor volume of ＜33 mL was 94.0% 
compared with 49.3% in patients with tumor volume of ≥33 
mL. In univariate analysis, large tumor diameter and volume, 
pelvic LN involvement and elevated pretreatment SCC-Ag 
levels were statistically significant relation to worse survival 
(Table 5). There was no significant relation between patient 
age, tumor histology or para-aortic LN involvement and OS. 
Using multivariate analysis, tumor volume of ＞33 mL 
(p=0.025) and positive pelvic LN involvement (p=0.044) re-
vealed a significantly unfavorable outcome on overall 
survival. The hazard ratio for tumor volume of ≥ 33 mL was 
8.31 (95% CI, 1.30 to 54.15) and for positive pelvic LN in-
volvement was 9.80 (95% CI, 1.07 to 90.09). Overall survival 
curves for tumor volume and pelvic LN involvement were 
shown in Fig. 1. 
DISCUSSION
Tumor size and tumor infiltration into surrounding normal 
tissue can be accurately estimated in surgically treated 
patients. However it is usually not available in patients treated 
with CCRT. Previous studies have shown that MRI indicates 
the closest correlation to actual tumor volume that is cur-
rently performable in the clinical setting.10 In the evaluation of 
cervical cancer mass, MRI has several benefits with compar-
ison to CT. The soft tissue contrast and multiplanar capability 
of MRI provides clear delineation of tumor. Tumor location 
including local invasion and diameter in T2 weighted MRI cor-
related well with that in surgical specimen.11,12 Therefore, 
more accurate tumor size measurement and assessment of in-
vasion to surrounding normal tissue, the depth of stromal in-
vasion and LN evaluation has been possible.
In this study, we evaluated the relationship of prognostic fac-
tors (tumor diameter, volume, LN involvement, age, histol-
ogy and pretreatment SCC-Ag) to treatment outcome in 75 
stage IIB cervical cancer patients treated with CCRT. Our re-
sults indicated that the tumor volume and pelvic LN involve-
ment were significantly associated with OS. However, the da-
ta showed that tumor diameter, pretreatment SCC-Ag levels 
and para-aortic LN involvement had a poor relationship with 
OS. Burghardt et al.4 reported that OS was more closely re-
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lated to tumor volume than to clinical or pathologic stage in 
early cervical cancer patients treated by radical hysterectomy 
and lymphadenectomy. In their series, 5-year survival rates of 
91% for patients with tumor volume less than 2.5 mL, 79% for 
patients with tumor volume 2.5 to 10 mL, 70% for those with 
tumor volume 10 to 50 mL, and 48% for those with tumor vol-
ume more than 50 mL. In advanced FIGO stage I and II tumors 
treated with radical radiotherapy, the treatment outcome was 
dependent on clinically determined tumor size rather than 
stage.9 Our results revealed that the tumor diameter of ≥4.5 
cm correlated with worse OS by univariate analysis, but there 
was no correlation with OS by multivariate analysis. In gen-
eral, tumor mass of stage IIB cervical cancer is larger than ear-
ly cervical cancer. We suppose that tumor volume is the ap-
propriate parameter to predict treatment outcome than tumor 
diameter in large tumor mass.
FIGO criteria currently used to stage cervical cancer do not 
account for LN involvement, but the LN metastasis is major 
factor to determining prognosis and proper treatment. 
Increasing tumor size and increasing depth of stromal in-
vasion correlated most strongly with LN metastasis and a 
shorter disease-free survival in previous studies of patients 
with FIGO stage 1B.3,13 The accuracy and sensitivity rates with 
MRI for detecting LN metastasis from cervical cancer are be-
tween 76 to 100% and 36 to 71%, respectively.14,15 However, 
the limitation of MRI is that it is not possible to differentiate 
metastatic LN from non-metastatic LN hyperplasia of similar 
size and shape. In our study, pelvic LN involvement correlated 
significantly with OS and PFS by multivariate analysis. 
Para-aortic LNs does not correlate with treatment outcome. 
The incidence of pelvic LN metastasis in stage II cervical can-
cer undergoing radical hysterectomy was approximately 35 to 
45.8%. Our data revealed that pelvic LN metastasis and 
para-aortic LN metastasis were 58.7% and 14.7%, respectively. 
Also, patients with positive pelvic LNs have a 5-year survival 
rate of 69.5% whereas patients with positive para-aortic LNs 
were higher than patients with positive pelvic LNs. Para-aort-
ic metastases were found in 4.5 to 7.2% of patients in this 
stage.16-18 Higher 5-year survival rates of ＞90% are reported 
among patients treated surgically with no evidence of LN 
metastasis, compared to patients with positive pelvic node 
(50 to 60%, 5-year survival) or para-aortic nodes (20 to 30%, 
5-year survival).19 Although it is accepted commonly that pa-
tients with para-aortic LN metastases have lower OS and 
higher recurrence, the incidence of pelvic or para-aortic LN in-
volvement and 5-year survival rates were relatively higher 
than previous studies. We can assume that a portion of LN in-
volvement on MRI might be actually LN hyperplasia.
In addition, actual parametrial involvement was pathologi-
cally confirmed in approximately 21 to 55% in the clinical 
stage IIB cervical cancer.16,20,21 This suggests that almost one 
half of the patients are overstaged due to difficulty in dis-
tinguishing parametrial extension from inflammatory change, 
endometriosis, adhesion, and irregular shape of large cervical 
tumor.20,21 The 5-year survival rate of stage stage IIB cervical 
cancer patients with radical hysterectomy ranged between 55 
to 77%.22 In comparison with our 5-year survival rates, a part 
of our patients might be overstaged. Exact evaluations of LN 
status in the staging of cervical cancer are essential to direct 
treatment and reduce morbidity. More recently, positron 
emission tomography is more sensitive than MRI or CT for de-
tecting LN metastases in patients with cervical cancer.23,24 
Therefore, other diagnostic modalities such as positron emis-
sion tomography or sentinel node biopsy may have a potential 
role for the exact assessment of LN metastases.
For imaging-based tumor size assessment, simple diameter 
measurement of three orthogonal diameters or three-dimen-
sional (3D) volumetry with region-of-interest (ROI) quanti-
tative image analysis are commonly used. The measurement 
of orthogonal tumor diameters is the simplest, fastest, and 
most practical methods extensively used in the radiology 
department. Simple diameter-based tumor measurement ap-
pears to be equivalent to contour tracing/ROI analysis 3D tu-
mor volumetry for tumor size assessment for predicting 
outcome.25,26 Diameter-based measurement can be easily 
computed as an ellipsoid-shaped tumor volume, but does not 
consider irregularities in tumor border and shape, which can 
be accounted for by 3D ROI volumetry. Thus it may be less ac-
curate because cervical cancers have irregular contour that de-
viate from the idealized ellipsoid volume.
Tumor histology (adenocarcinoma) and pretreatment SCC-Ag 
levels of ≥4.5 ng/mL revealed poor prognosis in PFS, but no 
correlation with OS. Generally, adenocarcinoma has a poor 
prognosis and relatively resistant response to radiation 
therapy.27 SCC-Ag levels correlate with the extent of the dis-
ease, the response to treatment, survival and recurrence.28 
There were only 9 patients with adenocarcinoma histology in 
our study. The results may not have been large enough to be 
able to make a clear declaration. Thus, we suggest that a pro-
spective study involving a large cohort of patients will be re-
quired to confirm this possibility.
We conclude that in patient with stage IIB cervical cancer, 
tumor volume and pelvic LN involvement provided possibility 
to predict OS. Therefore, optimal tumor volume and pelvic LN 
assessment by pretreatment MRI might be helpful to predict 
treatment outcome.
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